SKN | Citi Downgrades Boston Scientific as Cyberattack Recovery Adds to Competitive Pressure

Key Takeaways:

• Citiroup downgraded Boston Scientific from Buy to Neutral and reduced its price target from USD 57 to USD 50 as uncertainty surrounding the company’s recovery from an August cyberattack compounds existing competitive pressures.

• Citi has lowered its Boston Scientific estimates eight times this year, most recently on September 9, while the company has warned that the August 25 global network outage could cause it to miss previously stated financial targets.

• The long-term product pipeline remains active, including the Tivus renal-denervation platform, the company’s re-entry into TAVR through MiRus, and the Seismiq coronary intravascular lithotripsy catheter, but several growth initiatives require time to reach commercial scale.

Cyberattack Recovery Creates Greater Near-Term Earnings Uncertainty

Boston Scientific is facing a more complicated operating environment after the August 25 cyberattack caused a global network outage. The company subsequently reported that operations had been restored and that it was working through a backlog of product orders.

Boston Scientific also said the incident was no longer affecting enrollment of new patients in remote-monitoring programs for cardiac device implants, including pacemakers and cardioverter-defibrillators.

The recovery nevertheless remains difficult to quantify. Citi’s analysts have already reduced their estimates eight times during 2026, with the latest revision coming on September 9 after Boston Scientific disclosed that it could miss previous financial targets.

For investors, the central issue is therefore not simply whether systems have been restored, but how long the operational and financial consequences of the disruption will continue.

Cardiac Businesses Face Separate Competitive Headwinds

The cyberattack is occurring alongside pressure on two important cardiac franchises.

Citi expects Watchman sales to decline 7.6% in the second half of 2026 and 8.8% in 2027. The analysts also identified uncertainty surrounding pending physician reimbursement for the Watchman franchise as an additional challenge.

Farapulse is facing increased competition in pulsed-field ablation, with Citi expecting pressure to persist into early 2028, when new Farawave catheters are expected to debut.

This combination makes the earnings outlook more difficult to assess. Cybersecurity-related disruption affects the timing and recovery of operations, while competition and reimbursement issues affect the underlying growth trajectory of specific product franchises.

Citi Reduces Its Valuation Reference as Recovery Visibility Remains Limited

Citi moved its rating from Buy to Neutral and lowered its target price from USD 57 to USD 50.

The analysts indicated that their confidence in the timing of a full recovery remains limited. Their assessment reflects uncertainty over how long the cybersecurity-related effects could persist and whether additional estimate revisions may be necessary.

Boston Scientific shares have declined more than 13% over the past month and were trading near USD 44, according to the supplied source. Over the same period, the S&P 500 was down approximately 1%.

The divergence illustrates the degree to which company-specific uncertainty has affected the stock relative to the broader market.

Long-Term Pipeline Provides a Different Investment Horizon

Citi nevertheless described Boston Scientific’s future product pipeline as robust.

The Tivus ultrasound platform for renal denervation remains in clinical development following Boston Scientific’s USD 600 million acquisition of SoniVie in May 2025. The company is also re-entering the transcatheter aortic valve replacement market through its USD 1.5 billion investment this year in valve developer MiRus.

The TAVR opportunity has a longer development timeline, with an estimated two to three years potentially required to obtain FDA approval.

In the nearer term, Boston Scientific has reported positive pivotal-study results for its Seismiq coronary intravascular lithotripsy catheter and submitted the device for regulatory review. A commercial launch is estimated for early 2027.

What Matters for Global Wealth Investors

For HNWIs with exposure to healthcare equities, Boston Scientific illustrates the difference between near-term earnings visibility and longer-term innovation potential.

The company retains multiple product-development opportunities, but the timing of those opportunities does not immediately resolve the uncertainty surrounding cyberattack recovery, Watchman demand, reimbursement and Farapulse competition.

The next material indicators will therefore include evidence that the operational backlog is normalizing, confirmation of financial guidance, developments in Watchman reimbursement, Farapulse market performance and progress toward the Seismiq launch.

Closing Insights

Citi’s downgrade reflects a reduction in visibility rather than a rejection of Boston Scientific’s longer-term product pipeline. The company is recovering from a major cybersecurity disruption while simultaneously navigating competitive and reimbursement pressures in important cardiac businesses. For private portfolios, the key distinction is between the timing of near-term earnings recovery and the potential contribution from products still several years from commercial maturity.

For a confidential discussion regarding retail banking strategy, insurance distribution models, customer loyalty ecosystems, digital financial services, or cross-border financial innovation opportunities, contact our senior advisory team.